Sildenafil for pulmonary hypertension: need for evidence generation.

摘要: Background: The present meta-analysis was conducted with the aim of comparing usefulness sildenafil for management pulmonary hypertension (PH). Methods: A systematic electronic and manual search to retrieve all published unpublished randomized clinical trials in PH. Pertinent data related various outcomes were extracted. Sildenafil planned comparison placebo, prostacyclin analogs endothelin receptor antagonists. For continuous weighted mean difference used while fixed or random effects models dichotomous data. Revman (Version 4.2) calculations. Results: Five studies a total 190 patients included final analysis. As compared placebo showed significant improvement 6-min walk test (68.90 (95% Cl 31.14 -106.65), p = 0.0003), artery pressure (-13.04 - 25.94 -0.15), 0.05), cardiac index (0.39 CI 0.24- 0.54), < 0.00001), Borg dyspnea score (-1.23 -1.36 -1.10), vascular resistance (-171 -300 -30.90), 0.02), functional class (6.48 2.74 15.33), 0.001) nonsignificant change right atrial worsening. No study satisfied inclusion criteria analogs. In bosentan, did not show any concern. Conclusion: conclusion, shown produce as placebo. There no between bosentan outcomes. is definite need conducting adequately powered controlled ofsildenafil it also other treatments approved use